• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant

Eli Lilly’s Oral GLP-1 Shows Positive Trial Results for Type 2 Diabetes

by Jasmine Pennic 04/17/2025 Leave a Comment

Lilly's Oral GLP-1 Shows Positive Phase 3 Results for Type 2 Diabetes

What You Should Know:  - Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone.  - Orforglipron stands out as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3
Read More

FDA Clears Dexcom G7 15 Day Continuous Glucose Monitoring System

by Jasmine Pennic 04/10/2025 Leave a Comment

FDA Clears Dexcom G7 15 Day Continuous Glucose Monitoring System

What You Should Know:  - Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.   - The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and
Read More

DME Providers Lead to Better CGM Adherence and Lower Healthcare Costs Compared to Pharmacies

by Jasmine Pennic 03/25/2025 Leave a Comment

DME Providers Lead to Better CGM Adherence and Lower Healthcare Costs Compared to Pharmacies

What You Should Know:  - New research published in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association, reveals that patients receiving continuous glucose monitors (CGM) through durable medical equipment (DME) providers demonstrate significantly higher adherence and lower healthcare costs compared to those using pharmacy channels.  - The study, titled "Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Healthcare Costs: A
Read More

Glooko Integrates Abbott FreeStyle Libre CGM, Enhancing Diabetes Management

by Jasmine Pennic 03/24/2025 Leave a Comment

Abbott Unveils FreeStyle Libre 3 Plus: World's Smallest CGM Sensor with Future AID Compatibility

What You Should Know:  - Glooko, a provider of integrated digital health solutions for diabetes management, has announced a significant expansion of its platform's capabilities with the integration of Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) systems in the United States.  - The newly implemented integration allows individuals with diabetes to seamlessly synchronize data from their FreeStyle Libre CGM systems with other vital health metrics, including insulin
Read More

Automated Insulin Delivery: Tandem Diabetes Unveils Control-IQ+ Enhancements

by Jasmine Pennic 03/19/2025 Leave a Comment

Automated Insulin Delivery: Tandem Diabetes Unveils Control-IQ+ Enhancements

What You Should Know:  - Tandem Diabetes Care, a leader in insulin delivery and diabetes technology announced the U.S. commercial launch of Control-IQ+ technology.  - This update provides users with greater flexibility and control over their diabetes management. The expanded parameters and enhanced features of Control-IQ+ are designed to address a broader range of individual needs, making automated insulin delivery more accessible and effective. Automated Insulin Delivery
Read More

Sequel Med Tech’s twiist AID System to Integrate Abbott’s FreeStyle Libre 3 Plus

by Jasmine Pennic 03/18/2025 Leave a Comment

Sequel Med Tech's twiist AID System to Integrate Abbott's FreeStyle Libre 3 Plus

What You Should Know:  - Sequel Med Tech, LLC, a company focused on developing cutting-edge insulin delivery technologies, has announced that its innovative twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, will be the first to integrate Abbott’s FreeStyle Libre 3 Plus sensor, a continuous glucose monitoring (CGM) device. - The integration marks a pivotal moment for individuals with type 1 diabetes (T1D). The twiist AID System, expected to launch in Q2 2025, is
Read More

Senseonics and Ascensia Diabetes Care Integrate Eversense® 365 CGM with SweetSpot™ Platform

by Fred Pennic 02/26/2025 Leave a Comment

Senseonics and Ascensia Diabetes Care Integrate Eversense® 365 CGM with SweetSpot™ Platform

What You Should Know:  - Senseonics Holdings and Ascensia Diabetes Care today announced the integration of the Eversense® 365 Continuous Glucose Monitoring (CGM) System with the SweetSpot™ diabetes management platform in the U.S.  - The collaboration aims to improve patient care and streamline diabetes management for endocrinology practices and their patients. Enhance Diabetes Management and Improve Patient Outcomes The integration allows SweetSpot to seamlessly access and
Read More

Tandem Diabetes Care Receives FDA Clearance for Control-IQ+ Technology for Type 2 Diabetes

by Jasmine Pennic 02/25/2025 Leave a Comment

Tandem Diabetes Care Receives FDA Clearance for Control-IQ+ Technology for Type 2 Diabetes

What You Should Know:  - Tandem Diabetes Care, a insulin delivery and diabetes technology company, announced that its Control-IQ+ technology has received clearance from the U.S. Food and Drug Administration (FDA) for use by adults with type 2 diabetes.  - The expanded indication builds on the success of Control-IQ+ in type 1 diabetes and offers a new automated insulin delivery (AID) option for individuals with type 2 diabetes. Improve Glycemic Control for Adults with Type 2
Read More

GoodRx: The Average Price Per Insulin Unit Dropped 42%

by Jasmine Pennic 01/20/2025 Leave a Comment

What You Should Know:  - The average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19, in mid-2024, according to a new report from GoodRx. The drop represent the lowest average recorded in a decade.  - Thanks to the Inflation Reduction Act and voluntary price cuts by major insulin manufacturers, prices have seen significant declines. Products like Lantus, Novolin N, Humalog, and Humulin N are now more affordable than they have been in years. Insulin Costs
Read More

Dexcom Introduces Generative AI Platform for Glucose Biosensing

by Jasmine Pennic 12/17/2024 Leave a Comment

Dexcom Introduces Generative AI Platform for Glucose Biosensing

What You Should Know:  - Dexcom, the global leader in continuous glucose monitoring (CGM), has achieved another groundbreaking milestone by launching the first generative AI (GenAI) platform in glucose biosensing technology, Stelo.  - The Stelo platform analyzes individual health data patterns to provide personalized insights and recommendations for improving metabolic health. AI-Powered Personalized Guidance The Dexcom GenAI platform leverages Google Cloud's Vertex AI and
Read More

  • Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 21
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |